INMD
InMode Ltd.
INMD has lower modeled downside risk, despite its lower overall score.
OSCR
Oscar Health, Inc.
OSCR has the edge over INMD overall, supported by stronger fundamentals and stronger modeled upside.
INMD Fundamentals
| Metric | Status |
|---|---|
| Stable | |
| Stable | |
| Healthy | |
| Strong |
INMD's cash flow and balance sheet are currently healthy, and its revenue and profitability are stable.
OSCR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Healthy | |
| Strong | |
| Strong |
OSCR's revenue, profitability, cash flow and balance sheet are all currently healthy.
INMD PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 9x | $11.06 | -16% |
| Forward | 9.8x | $13.19 | — |
| Current | 11x | $13.19 | — |
| Fair | 15x | $18.29 | +39% |
| Expensive | 35x | $43.04 | +226% |
Historical ranges are pointers, not guarantees.
INMD's PE is in its fair range at 11x. On analysts' estimates for next year's earnings, today's price would be 9.8x, in its cheap range.
OSCR PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Forward | 12x | $31.94 | — |
| Current | 13x | $31.94 | — |
| Cheap | 21x | $52.73 | +65% |
| Fair | 35x | $87.23 | +173% |
| Expensive | 130x | $322 | +907% |
Historical ranges are pointers, not guarantees.
OSCR has the edge over INMD in the historical PE scenario, which offers more potential upside but is not a forecast.
INMD Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Stable | |
| Stable | |
| Weakening | |
| Limited | |
| Moderate |
Analysts expect INMD's profitability to weaken, with its earnings and revenue holding steady.
OSCR Forward outlook
| Metric | Outlook |
|---|---|
| Improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
OSCR has the edge over INMD on the outlook, with more favorable earnings and revenue expectations.
INMD Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $1.35 | +10% |
| Q2 2026 | $1.23 | -50% |
| Q2 2025 | $2.47 | +42% |
| Q2 2024 | $1.74 | -19% |
| Q1 2024 | $2.11 | +5% |
| Q4 2023 | $2.30 | +21% |
| Q3 2023 | $2.10 | +1.4% |
| Q2 2023 | $2.14 | +6.5% |
| Q1 2023 | $2.01 | +2% |
INMD has the edge over OSCR on earnings, with more consistent year-over-year improvement.
OSCR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $2.61 | +5.6% |
| Q3 2026 | $2.47 | +$3.47 |
| Q2 2026 | $1.45 | +$2.14 |
| Q1 2026 | -$0.54 | -235% |
| Q4 2025 | -$1.69 | -1790% |
| Q3 2025 | -$1.00 | -$0.92 |
| Q2 2025 | -$0.69 | -$0.54 |
| Q1 2025 | $0.40 | +$0.82 |
| Q4 2024 | $0.10 | +$1.32 |
OSCR has returned to profit: it earned $2.47 per share over the past year, after losing money the year before.
INMD Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $95.6M | 0% |
| Q1 2026 | $82M | +5.3% |
| Q4 2025 | $103.9M | +6.1% |
| Q3 2025 | $93.2M | -28% |
| Q2 2025 | $95.6M | +11% |
| Q1 2025 | $77.9M | -3% |
| Q4 2024 | $97.9M | -23% |
| Q4 2024 | $130.2M | +5.8% |
INMD's revenue has slid since its 2023 peak: $96M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 13% | -11 points |
| Q1 2026 | 12% | -7.8 points |
| Q4 2025 | 25% | -3.4 points |
| Q3 2025 | 22% | -15 points |
| Q2 2025 | 24% | +2.8 points |
| Q1 2025 | 20% | -2.5 points |
| Q4 2024 | 28% | -12 points |
| Q4 2024 | 37% | -0.6 points |
INMD has the edge over OSCR on profitability, with a higher operating margin.
OSCR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $5.1B | +72% |
| Q2 2026 | $4.9B | +70% |
| Q1 2026 | $4.6B | +53% |
| Q4 2025 | $2.8B | +17% |
| Q3 2025 | $3B | +23% |
| Q2 2025 | $2.9B | +29% |
| Q1 2025 | $3B | +42% |
| Q4 2024 | $2.4B | +67% |
OSCR has the edge over INMD on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 3.5% | +7.8 points |
| Q2 2026 | 8% | +16 points |
| Q1 2026 | 15% | +5.4 points |
| Q4 2025 | -12% | -5.7 points |
| Q3 2025 | -4.3% | -2.3 points |
| Q2 2025 | -8.1% | -11 points |
| Q1 2025 | 9.8% | +1.1 points |
| Q4 2024 | -6.2% | +4 points |
OSCR's operating margin was 3.5% last quarter, up 7.8 points from the same quarter a year ago.
INMD Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $20.8M | -13% |
| Q1 2026 | $15.2M | +9% |
| Q4 2025 | $24.4M | -24% |
| Q3 2025 | $27M | -21% |
| Q2 2025 | $24M | -43% |
| Q1 2025 | $14M | -42% |
| Q4 2024 | $32.2M | -45% |
| Q4 2024 | $34M | -13% |
INMD's free cash flow has been positive every quarter for seven years: $87M over the past year, down 16% from the year before.
OSCR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$1.2B | -$238.2M |
| Q2 2026 | $2.1B | +316% |
| Q1 2026 | $2.6B | +200% |
| Q4 2025 | $662.8M | +95% |
| Q3 2025 | -$973.7M | -$466M |
| Q2 2025 | $499.8M | +2.1% |
| Q1 2025 | $869.5M | +38% |
| Q4 2024 | $340M | +17% |
OSCR has the edge over INMD on cash flow, with more consistent year-over-year improvement.
INMD Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -7.1% | -4.6M shares |
| 1 year | -6.7% | -4.3M shares |
| 3 years | -31% | -26.3M shares |
| 5 years | -31% | -26.4M shares |
| Available history | -24% | -18.6M shares |
INMD has the edge over OSCR on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q2 2026 | $56.5M |
| Q1 2026 | $31.2M |
| Q4 2025 | $1.9M |
| Q3 2025 | $5.2M |
| Q2 2025 | $28.1M |
| Q1 2025 | $100M |
| Q4 2024 | $119.8M |
| Q4 2024 | $76.6M |
INMD spent $95M buying back its own shares over the past year, down 71% from the year before.
OSCR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +3.9% | +13M shares |
| 1 year | +34% | +87.2M shares |
| 3 years | +55% | +123M shares |
| 5 years | +66% | +138M shares |
| Available history | +71% | +143M shares |
OSCR has 346M diluted shares, up 34% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
INMD Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q2 2026 | -4.7x | Net Cash |
| Q1 2026 | -3.8x | Net Cash |
| Q4 2025 | -2.6x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -1.5x | Net Cash |
| Q2 2024 | -0.5x | Net Cash |
| Q1 2024 | -0.6x | Net Cash |
| Q4 2023 | -0.6x | Net Cash |
INMD has the edge over OSCR on leverage, with a lower net debt burden relative to earnings.
OSCR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -4.2x | Net Cash |
| Q2 2026 | -5.5x | Net Cash |
| Q1 2026 | -110.0x | Net Cash |
| Q1 2025 | -9.7x | Net Cash |
| Q4 2024 | -13.7x | Net Cash |
| Q3 2024 | -10.1x | Net Cash |
| Q2 2024 | -24.0x | Net Cash |
| Q1 2024 | -217.7x | Net Cash |
OSCR has more cash than debt.
INMD Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 34.2 | Neutral |
| Stochastic | 4.9 | Oversold |
INMD's weekly RSI is 34 (neutral) and its Stochastic is 5 (oversold).
OSCR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 58.7 | Neutral |
| Stochastic | 44.9 | Neutral |
OSCR's weekly RSI is 59 (neutral) and its Stochastic is 45 (neutral).
INMD PE vs Healthcare Sector
| Metric | INMD | Sector median | Relative |
|---|---|---|---|
| PE | 11x | 26x | 59% below |
| PE % | 35 | 29 | 6 pts above |
INMD has the edge over OSCR on valuation relative to its sector.
OSCR PE vs Healthcare Sector
| Metric | OSCR | Sector median | Relative |
|---|---|---|---|
| PE | 13x | 26x | 50% below |
| PE % | 3 | 35 | 32 pts below |
OSCR is trading at 13x earnings, a 50% discount to the Healthcare sector's median of 26x, though its earnings don't support one.
INMD Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $13.8 | 4.4% below |
| 20 week MA | $14.5 | 9.3% below |
| 50 week MA | $14.3 | 7.8% below |
| 100 week MA | $14.9 | 12% below |
| 200 week MA | $20.3 | 35% below |
INMD is in a downtrend: it's below all five of its weekly moving averages, and 35% below its 200-week average.
OSCR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $31.2 | 2.3% above |
| 20 week MA | $31.1 | 2.8% above |
| 50 week MA | $22.9 | 39% above |
| 100 week MA | $19.3 | 65% above |
| 200 week MA | $15.5 | 106% above |
OSCR has the edge over INMD on trend strength, trading above more of its moving averages.
INMD Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $19.5 | $23.8 | +22% |
| 2021 | $23.8 | $72.1 | +203% |
| 2022 | $72.1 | $35.4 | -51% |
| 2023 | $35.4 | $22.2 | -37% |
| 2024 | $22.2 | $17.0 | -23% |
| 2025 | $17.0 | $14.6 | -14% |
| 2026 YTD | $14.6 | $13.2 | -9.8% |
INMD has finished four years in a row lower, and it's down 9.8% so far in 2026.
OSCR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $31.0 | $8.02 | -74% |
| 2022 | $8.02 | $2.21 | -72% |
| 2023 | $2.21 | $9.15 | +314% |
| 2024 | $9.15 | $13.8 | +51% |
| 2025 | $13.8 | $14.9 | +8% |
| 2026 YTD | $14.9 | $31.9 | +114% |
OSCR has the edge over INMD on returns for 2026, with the stronger performance.